The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Emerging biomarkers for predicting immune-related adverse events in NSCLC
Umair Mahmood, BSc, MSc, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses promising developments in identifying biomarkers linked to immune checkpoint inhibitor toxicity when treating non-small cell lung cancer (NSCLC). He highlights the role of inflammatory interleukin-6 cytokines and chemokines, as well as reduced anti-inflammatory cytokines, in influencing patient outcomes. A key takeaway from recent data is the potential predictive value of a reduced baseline neutrophil-to-lymphocyte ratio—a finding seen in previous studies but still requiring validation. These insights may help stratify high-risk patients and personalize treatment strategies in the future. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
